GANX
NASDAQ
US
Gain Therapeutics, Inc. - Common Stock
$1.85
▼ $-0.09
(-4.64%)
Vol 521K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$123.8M
ROE
-222.6%
Margin
-6393.8%
D/E
7.18
Beta
0.03
52W
$1–$4
Wall Street Consensus
11 analysts · Apr 20264
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
HURA
TuHURA Biosciences Inc
$45.9M
ANIX
Anixa Biosciences Inc
$102.7M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
COEP
Coeptis Therapeutics Holdings Inc
$76.1M
XGN
Exagen Inc
$137.8M
EXOZ
eXoZymes Inc
$91.4M
Earnings
Beat rate: 80.0%
Next Report
May 12, 2026
EPS Estimate: $-0.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.14 | — | — |
| Dec 2025 | $-0.15 | $-0.11 | +$0.04 |
| Sep 2025 | $-0.15 | $-0.15 | +$0.00 |
| Jun 2025 | $-0.17 | $-0.19 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$4.5M | -$3.8M | -$4.5M | -$5.8M | -$5.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -222.6% | -222.6% | -222.6% | -222.6% | -222.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -6393.8% | -6393.8% | -6393.8% | -6393.8% | -6393.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 12.21 | 12.21 | 12.21 | 12.21 | 7.18 | 7.18 |
| Current Ratio | 1.79 | 1.79 | 1.79 | 1.79 | 2.52 | 2.52 |
Key Ratios
ROA (TTM)
-135.5%
P/S (TTM)
774.05
P/B
7.6
EPS (TTM)
$-0.95
CF/Share
$-1.43
52W High
$4.34
52W Low
$1.41
$1.41
52-Week Range
$4.34
Financial Health
Free Cash Flow
-$4.9M
Net Debt
-$8.2M
Cash
$8.8M
Total Debt
$605K
As of Sep 30, 2025
How does GANX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GANX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
774.1
▲
5924%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
7.6
▲
211%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GANX profitability vs Biotechnology peers
ROE
-222.6%
▼
231%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-6393.8%
▼
2130%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-135.5%
▼
190%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
GANX financial health vs Biotechnology peers
D/E ratio
7.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.5
▼
43%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.0
▼
97%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
GANX fundamentals radar
GANX
Peer median
Industry
GANX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GANX vs peers: key metrics
Top Holders
Top 5: 12.04%Marshall Wace LLP
4.32%
$3.0M
Potomac Capital Management,…
2.63%
$1.8M
Jones Financial Companies, …
1.83%
$1.3M
Susquehanna International G…
1.78%
$1.3M
Vanguard Group Inc
1.48%
$1.0M
As of Dec 31, 2025
Latest News
No related news yet